首页> 外文会议>IUPAC 10th International conference on novel materials and their synthesis: Book of abstracts >Solution Property and Blood Compatibility of Hemoglobin-Albumin Cluster 'HemoAct™'
【24h】

Solution Property and Blood Compatibility of Hemoglobin-Albumin Cluster 'HemoAct™'

机译:血红蛋白-白蛋白簇“ HemoAct™”的溶液性质和血液相容性

获取原文
获取原文并翻译 | 示例

摘要

In the last few decades, hemoglobin (Hb)-based O_2 carriers have been developed as a red blood cell (RBC) substitute. However, none satisfies all requirements for clinical use. An important concern (side effect) is increased blood pressure which is caused by NO scavenging by Hb diffused into extra vascular space. More recently, we have synthesized covalent core-shell structured protein clusters of Hb and human serum albumin (HSA) (Hb-HSA_m, m=2-4) by linkage of Hb surface lysines to HSA cysteine-34 via an a-succinimidyl-ε-maleimide crosslinker. The obtained Hb-HSA_m cluster solution ([Hb]=5 g/dL), -HemoAct™", could become a new type of RBC alternative and O_2-therapeutic reagent in transfusion medicine. This paper presents the structure, solution property, and blood compatibility of the -HemoAct™" artificial O_2-carrier. HPLC and Native-PAGE measurements revealed that the major component of cluster is Hb-HSA_3 heterotetramer. The average number of HSA binding per Hb was 2.8 (the diameter: 8.9±2.5 nm). The isoelectric point (pI=5.1) was almost identical to the value of HSA. This means that the surface net charge of the cluster is satisfactorily negative to be used as a transfusion medicine. HemoAct™ showed a moderately high O_2-affmity compared to native Hb. The P_(50) value (O_2 partial pressure where Hb is half-saturated with O_2) is 9 Torr. The viscosity of 2.8 cP at 230 s~(-1) is slightly lower than that of whole blood. After the addition of HemoAct™ into whole blood at 10, 20, and 40 vol%, no significant time dependence was observed in the numbers of RBCs, white blood cells, or platelets for 6 h at 37 ℃. The blood coagulation parameters were also unaltered. These results suggest that the HemoAct™ has no effect on blood cell components in vitro. All rats (Wister rats, male) given HemoAct™ have been alive for 7 days after the infusion. During the observation period, no remarkable reaction was seen in the appearance of the animals. Parameters of the clinical blood serum chemistry were all in the normal ranges.
机译:在过去的几十年中,基于血红蛋白(Hb)的O_2载体已被开发为红细胞(RBC)的替代品。但是,没有一个能够满足临床使用的所有要求。一个重要的问题(副作用)是血压升高,这是由于Hb扩散到多余的血管腔中而清除NO引起的。最近,我们通过Hb表面赖氨酸通过a-琥珀酰亚胺基-连接到HSA半胱氨酸34,合成了Hb和人血清白蛋白(HSA)(Hb-HSA_m,m = 2-4)的共价核-壳结构蛋白簇。 ε-马来酰亚胺交联剂。所得的Hb-HSA_m簇溶液([Hb] = 5 g / dL),-HemoAct™”可以成为输血医学中一种新型的RBC替代物和O_2治疗剂。 -HemoAct™“人工O_2-载体的血液相容性。 HPLC和Native-PAGE测量表明,簇的主要成分是Hb-HSA_3异四聚体。每Hb结合HSA的平均数为2.8(直径:8.9±2.5nm)。等电点(pI = 5.1)几乎与HSA的值相同。这意味着该簇的表面净电荷令人满意地为负,以用作输注药物。与天然Hb相比,HemoAct™显示出较高的O_2亲和力。 P_(50)值(Hb用O_2半饱和的O_2分压)为9 Torr。 230 s〜(-1)时的粘度为2.8 cP,略低于全血。将HemoAct™以10、20和40 vol%的浓度添加到全血中后,在37℃下6 h的RBC,白细胞或血小板的数量没有明显的时间依赖性。凝血参数也未改变。这些结果表明,HemoAct™在体外对血细胞成分没有影响。输注后,所有使用HemoAct™的大鼠(Wister大鼠,雄性)均存活7天。在观察期间,在动物的外观上没有观察到明显的反应。临床血清化学指标均在正常范围内。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号